Groowe Groowe / Newsroom / SCNX
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

SCNX News

Scienture Holdings, Inc. Common Stock

Form 8-K

sec.gov
SCNX

SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™

globenewswire.com
SCNX

Form 8-K

sec.gov
SCNX

SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027

globenewswire.com
SCNX

Form 8-K

sec.gov
SCNX

SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

globenewswire.com
SCNX

Form 8-K

sec.gov
SCNX

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

globenewswire.com
SCNX

Scienture Holdings, Inc. Announces Reverse Stock Split

globenewswire.com
SCNX

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

globenewswire.com
SCNX